RxDoctor Payments Data

Britten Williams, APRN

Family · Jonesboro, ARNPI 1538825443

Payments from drug & device makers

$4,132in general payments, 2019–2025

Across 177 payments — averaging $23.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • AbbVie$356
  • Sumitomo Pharma America, Inc.$302
  • Astellas Pharma US Inc$187
  • Endo USA, Inc.$184
  • Endo Pharmaceuticals Inc.$182
  • plus $2K from 23 others

What the payments were for

  • Travel & lodging$1714%
  • Food & beverage$3,87694%
  • Education$852%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,132 in reported general payments places this provider in the 90th percentile of 2,103 family providers in Arkansas.

See all family providers in Arkansas

Medicare billing

Part B allowed, 2024
$52,541
Medicare patients
601
Services billed
959

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ErleadaApalutamide12$166,886
MyrbetriqMirabegron166$86,346
GemtesaVibegron120$67,482
ElmironPentosan Polysulfate Sodium13$15,340
Tamsulosin Hcl649$10,935
Trospium Chloride95$4,635
Fesoterodine Fumarate ErFesoterodine Fumarate68$4,380
Testosterone23$3,506
Finasteride284$3,374
Solifenacin Succinate111$3,369
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst93$1,860
Potassium Citrate ErPotassium Citrate20$1,800
Alfuzosin Hcl ErAlfuzosin Hcl83$1,634
Desmopressin Acetate13$1,352
Testosterone Cypionate31$1,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonErleada$181$166,88612 claims
Astellas Pharma US IncMyrbetriq$187$86,346166 claims
Sumitomo Pharma America, Inc.Gemtesa$302$67,482120 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,103 family providers in Arkansas.

Other family in Jonesboro

See the full list for Arkansas

Where these figures come from

Is this you, or does something look wrong? →